Epizyme Inc. (EPZM)

11.85
0.13 1.11
NASDAQ : Health Technology
Prev Close 11.72
Open 11.67
Day Low/High 11.67 / 12.24
52 Wk Low/High 5.14 / 21.40
Volume 729.35K
Avg Volume 820.90K
Exchange NASDAQ
Shares Outstanding 79.17M
Market Cap 967.43M
EPS -2.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of August 16th Options Trading For Epizyme (EPZM)

First Week Of August 16th Options Trading For Epizyme (EPZM)

Investors in Epizyme Inc. saw new options begin trading this week, for the August 16th expiration.

Epizyme Announces Registration Path For Tazemetostat For Follicular Lymphoma And Provides Pipeline Updates And 2019 Guidance

Epizyme Announces Registration Path For Tazemetostat For Follicular Lymphoma And Provides Pipeline Updates And 2019 Guidance

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat...

Epizyme Earns $8 Million Milestone Payment From GlaxoSmithKline For Initiation Of Clinical Development For First-in-Class PRMT1 Inhibitor

Epizyme Earns $8 Million Milestone Payment From GlaxoSmithKline For Initiation Of Clinical Development For First-in-Class PRMT1 Inhibitor

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced it has earned an $8 million milestone payment from GlaxoSmithKline (GSK).

Epizyme Is Now Oversold (EPZM)

Epizyme Is Now Oversold (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Epizyme Announces Conference Call To Discuss Corporate Updates

Epizyme Announces Conference Call To Discuss Corporate Updates

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a conference call to discuss corporate updates today at 8:30 a.

Epizyme Reports Third Quarter 2018 Financial Results And Tazemetostat Progress

Epizyme Reports Third Quarter 2018 Financial Results And Tazemetostat Progress

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today reported financial results for the third quarter of 2018 and provided updates on its tazemetostat clinical development program.

Oversold Conditions For Epizyme (EPZM)

Oversold Conditions For Epizyme (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Epizyme Reports Positive Data On Tazemetostat In Epithelioid Sarcoma From Its Phase 2 Trial Cohort At ESMO

Epizyme Reports Positive Data On Tazemetostat In Epithelioid Sarcoma From Its Phase 2 Trial Cohort At ESMO

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced positive interim data from the fully enrolled epithelioid sarcoma cohort of its ongoing Phase 2 study of its lead candidate tazemetostat, a...

Epizyme To Present Updated Data On Tazemetostat From Full Phase 2 Study Cohort In Epithelioid Sarcoma At ESMO

Epizyme To Present Updated Data On Tazemetostat From Full Phase 2 Study Cohort In Epithelioid Sarcoma At ESMO

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, announced today that updated efficacy and safety data from the fully enrolled cohort of epithelioid sarcoma (ES) patients in its ongoing Phase 2 trial of...

Epizyme Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriter's Option To Purchase Additional Shares

Epizyme Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriter's Option To Purchase Additional Shares

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the closing of its underwritten public offering of 9,583,334 shares of its common stock at a public offering price of $9.

Interesting EPZM Put And Call Options For May 2019

Interesting EPZM Put And Call Options For May 2019

Investors in Epizyme Inc. saw new options begin trading this week, for the May 2019 expiration.

Epizyme Announces Pricing Of Public Offering Of Common Stock

Epizyme Announces Pricing Of Public Offering Of Common Stock

Epizyme, Inc. (Nasdaq:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the pricing of an underwritten public offering of 8,333,334 shares of its common stock at a price of $9.

Epizyme Announces Proposed Public Offering Of Common Stock

Epizyme Announces Proposed Public Offering Of Common Stock

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Epizyme Announces The U.S. Food And Drug Administration Lifts Partial Clinical Hold On Tazemetostat Clinical Program

Epizyme Announces The U.S. Food And Drug Administration Lifts Partial Clinical Hold On Tazemetostat Clinical Program

Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the U.

Epizyme To Participate In Upcoming Investor Conferences

Epizyme To Participate In Upcoming Investor Conferences

Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will present at the following upcoming investor conferences: Citi's 13th Annual Biotech Conference in Boston - Panel discussion...

Epizyme Reports Second Quarter 2018 Financial Results And Provides Business Updates

Epizyme Reports Second Quarter 2018 Financial Results And Provides Business Updates

Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today reported financial results for the second quarter of 2018 and provided key business updates.

Epizyme Becomes Oversold (EPZM)

Epizyme Becomes Oversold (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of EPZM February 2019 Options Trading

First Week Of EPZM February 2019 Options Trading

Investors in Epizyme Inc. saw new options become available this week, for the February 2019 expiration.

Epizyme Enters Oversold Territory (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting EPZM Put And Call Options For August 2018

Interesting EPZM Put And Call Options For August 2018

Investors in Epizyme Inc. saw new options become available this week, for the August 2018 expiration.

Commit To Purchase Epizyme At $7.50, Earn 13.2% Annualized Using Options

Commit To Purchase Epizyme At $7.50, Earn 13.2% Annualized Using Options

Investors eyeing a purchase of Epizyme Inc. stock, but cautious about paying the going market price of $11.97/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Epizyme Presents Preclinical Data On Novel G9a Program And Introduces Next Drug Development Candidate At The American Society Of Hematology Annual Meeting

Epizyme Presents Preclinical Data On Novel G9a Program And Introduces Next Drug Development Candidate At The American Society Of Hematology Annual Meeting

EZM8266 is the First of Three New Compounds to be Named as Part of Epizyme's Vision 2020

Epizyme Presents New Biomarker Data On Tazemetostat At The American Society Of Hematology Annual Meeting

Epizyme Presents New Biomarker Data On Tazemetostat At The American Society Of Hematology Annual Meeting

Data Highlights Company's Innovative Work in Translational Medicine to Identify Non-Hodgkin Lymphoma Patient Populations That May Derive Most Benefit

TheStreet Quant Rating: D (Sell)